Sandoz announced that it is in-licensing the commercial distribution rights to a respiratory inhalation medicine from Kindeva Drug Delivery. Princeton, N.J.-based Sandoz in-licensed the rights to the brand and authorized generic of Proventil HFDA (albuterol sulfate) inhalation aerosol, which is immediately available to U.S. patients, according to a news release. Albuterol sulfate is used to […]
HTX Urology set to participate in study for Urotronic’s prostate treatment device
Urotronic announced that HTX Urology is participating in an FDA-cleared study for a minimally invasive device for treating enlarged prostates. Plymouth, Minn.-based Urotronic’s Optilume BPH (benign prostatic hyperplasia, otherwise known as enlarged prostate) catheter system is an outpatient procedure designed to combine balloon dilation to open the prostate and local drug delivery to maintain symptom […]
Graphite Bio closes $150M Series B
Graphite Bio announced that it closed an oversubscribed Series B financing round with proceeds totaling $150 million. South San Francisco-based Graphite Bio’s funding is earmarked for the expansion and advancement into the clinic of its pipeline of investigational targeted gene integration therapies with curative potential for serious diseases, according to a news release. The company […]
Italfarmaco, Luye enter commercialization pact for transdermal Alzheimer’s treatment
Italfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD. Under the agreement, Milan, Italy-based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release. Italfarmaco gains the rights to commercialize in Germany, Italy, Portugal and Greece under […]
Glooko raises $30M Series D
Diabetes and obesity management tech developer Glooko announced today that it raised $30 million in a Series D financing round. Palo Alto, Calif.-based Glooko, which develops remote patient monitoring and chronic care management products including data management technologies for insulin delivery devices, said in a news release that proceeds from the financing will be used […]
Intec Pharma, Decoy Biosystems agree to merger
Intec Pharma (NSDQ:NTEC) announced that it entered into a definitive agreement over a merger with Decoy Biosystems. Jerusalem-based Intec Pharma said in a news release that the combined company is slated to grow an immunotherapy platform to battle a variety of tumor types and chronic viral infections with Decoy bringing to the table multi-targeted products […]
Oncopeptides launches Pepaxto multiple meyeloma treatment
Oncopeptides (STO:ONCO) announced today that it launched its Pepaxto drug for treating relapsed or refractory multiple myeloma. Boston-based Oncopeptides’ Pepaxto (melphalan flufenamide), which received accelerated FDA approval on Feb. 26, is now commercially available and the first patients are being treated with the drug, according to a news release. Pepaxto received approval in combination with […]
Savara closes $130M offering
Savara (NSDQ:SVRA) announced today that it closed its previously announced public offering with proceeds reaching approximately $130 million. Austin, Texas-based Savara last week announced the offering of 45.8 million shares of its common stock to the public for $1.45 per share, expecting proceeds of $113 million. However, the company today said in a news release […]
Bicara Therapeutics launches with $40M investment
Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]
Aurinia touts cost-effectiveness study of oral treatment for lupus nephritis
Aurinia Pharmaceuticals (NSDQ:AUPH) announced today that it received a favorable assessment of the cost-effectiveness of Lupkynis. Victoria, British Columbia-based Aurinia’s Lukynis (voclosporin) was evaluated in an independent analysis by the Institute for Clinical and Economic Review (ICER) in a revised evidence report issued on March 12, 2021, according to a news release. The evaluation found […]
